Newsroom

All News
  • All News
  • In the News
  • Press Releases
  • Publications
  • Events
KTVALogo-175x125

Surviving sepsis: Beth’s story

There are some unspoken rules in the TV news business, like always assume the microphone is hot and stay out of other photographers’ shots. Another is to keep the story succinct. Even on a one-hour broadcast, a general report may last a minute and a half, possibly two. But there...
Immunexpress.com

Immunexpress Appoints Jane Papadaki Markley as VP of Market Development and Commercial Operations

The addition represents the development of a global commercial framework in preparation for SeptiCyte™ RAPID launch Immunexpress, Inc. today announced that Jane Papadaki Markley has joined the company's Executive Team as Vice President of Market Development and Commercial Operations. "Jane's impressive ability to incorporate the commercial perspective into development strategies will be...
elsevierLogo

A pilot study of a novel molecular host response assay to diagnose infection in patients after high-risk gastro-intestinal surgery

SeptiCyte LAB measures the expression of four host-response RNAs in peripheral blood to distinguish sepsis from sterile inflammation. This study evaluates whether sequential monitoring of this assay has diagnostic utility in patients after esophageal surgery. Among 370 esophagectomy patients, 120 (32%) subjects developed a complication requiring ICU (re)admission, 63 (53%)...
PLOS

The effect of uncertainty in patient classification on diagnostic performance estimations

Background The performance of a new diagnostic test is typically evaluated against a comparator which is assumed to correspond closely to some true state of interest. Judgments about the new test’s performance are based on the differences between the outputs of the test and comparator. It is commonly assumed that...
genome web

Novacyt, Immunexpress Extend Sepsis Assay Development Partnership

French diagnostics firm Novacyt said today that its molecular testing division Primerdesign has extended its sepsis assay development contract with Immunexpress.   Specific terms of the deal were not disclosed.   Novacyt said the companies have been working together for three years, with Primerdesign providing Immunexpress with assay development services....
Immunexpress.com

Disagreement in Sepsis Diagnosis is Associated with Significant Antibiotic Overprescription

Immunexpress, Inc., a molecular diagnostics company based in Seattle, announced the publication of a study, in the Journal of Intensive Care, demonstrating the challenge physicians face in making accurate and consistent clinical diagnoses of sepsis in intensive care patients. Sepsis is an illness caused by the body's overwhelming immune response to an infection,...
bioworld-logo

Medical Device Daily – Other News to Note

Immunexpress Inc., of Seattle, reported a partnership with the DRIVe Solving Sepsis Initiative, a collaboration in which the Division of Research, Innovation...
genome web

Immunexpress Wins $745K HHS Contract for Rapid Sepsis Assay

Immunexpress said today that it has received a funding commitment of $744,739 from the US Department of Health and Human Services (HHS) for the development and commercialization of its SeptiCyte sample-to-result sepsis assay.   The RT-qPCR assay, which received US Food and Drug Administration 510(k) clearance in early 2017, is...
Immunexpress.com

Immunexpress Secures BARDA Contract for the Continued Development of SeptiCyte™ for the Rapid and Accurate Diagnosis of Sepsis

Immunexpress, Inc. today announced its partnership with the DRIVe Solving Sepsis Initiative, a collaboration in which DRIVe will contribute $744,739 of a $3.2M project for the development and commercialization of Immunexpress' SeptiCyte™ technology on the Biocartis Idylla™ platform. This development will result in a tool capable of a 90-minute, sample-to-result diagnosis in patients suspected...
expert-review-logo

Profile of the SeptiCyte™ LAB gene expression assay to diagnose infection in critically ill patients.

Sepsis is a severe and frequently occurring clinical syndrome, caused by the inflammatory response to infections. Recent studies on the human transcriptome during sepsis have yielded several gene-expression assays that might assist physicians during clinical assessment of patients suspected of sepsis. SeptiCyte™ LAB (Immunexpress, Seattle, WA) is the first gene...
soundcloud-logo

Future In A Flash – Rollie Carlson CEO of Immunexpress

As the JP Morgan Healthcare Conference convenes in San Francisco, we’re offering a glimpse into the future of the industry, from the C-suites of the most promising pharma, biopharma, medtech, tech and telehealth companies in the nation. Today we explore the latest trends in rapid diagnostics with Immunexpress CEO, Rollie...
BioCentury-large

Sepset’s Sepsis Signature

BioCentury Senior Writer Michael Leviten discusses gene expression tests that could speed up diagnosis of sepsis.

If you are a member of the media, please contact:

Maggie Beller
Russo Partners
(646) 942-5631
maggie.beller@russopartnersllc.com